Search Results - "Cetto, G."

High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy by Pasini, F., de Manzoni, G., Pedrazzani, C., Grandinetti, A., Durante, E., Gabbani, M., Tomezzoli, A., Griso, C., Guglielmi, A., Pelosi, G., Maluta, S., Cetto, G. L., Cordiano, C.

“…Background: This phase I study was aimed at defining the toxicity profile and pathological response rate of a neoadjuvant schedule including weekly docetaxel…”
Get full text

End of life in cancer patients: drugs or words? by Aitini, E., Adami, F., Cetto, G.L.

Get full text

Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study by Celio, L., Sternberg, C. N., Labianca, R., La Torre, I., Amoroso, V., Barone, C., Pinotti, G., Cascinu, S., Di Costanzo, F., Cetto, G. L., Bajetta, E.

“…Background: This clinical trial assessed the efficacy of pemetrexed combined with oxaliplatin (PEMOX) in patients with advanced gastric cancer (AGC). Patients…”
Get full text

Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial by Paccagnella, Adriano, Favaretto, A., Oniga, F., Barbieri, F., Ceresoli, G., Torri, W., Villa, E., Verusio, C., Cetto, G.L., Santo, A., De Pangher, V., Artioli, F., Cacciani, G.C., Parodi, G., Soresi, F., Ghi, M.G., Morabito, A., Biason, R., Giusto, M., Mosconi, P., Chiarion Sileni, V.

“…Background: In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1–2 months on median survival versus best supportive care…”
Get full text

Correlations between family history and cancer characteristics in 2256 breast cancer patients by MOLINO, A, GIOVANNINI, M, PEDERSINI, R, FRISINGHELLI, M, MICCIOLO, R, MANDARA, M, PAVARANA, M, CETTO, G. L

“…A comparison of 692 early invasive breast cancer with, and 1564 without, a family history of breast cancer showed that the former were younger at diagnosis…”
Get full text

Carboplatin and Gemcitabine in First-Line Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer: Data from a Retrospective Study by Genestreti, G., Giovannini, N., Frizziero, M., Maglie, M., Sanna, S., Cingarlini, S., Molino, A.M., Piciucchi, S., Cetto, G.L., Santo, A.

“…We retrospectively evaluated elderly patients with advanced non-small cell lung cancer (NSCLC) treated with carboplatin (AUC 4-5) and gemcitabine (1,000-1,200…”
Get full text

A good death for cancer patients: still a dream? by Aitini, E., Cetto, G. L.

Get full text

Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a long-term retrospective analysis by Bonomi, M., Nortilli, R., Molino, A., Sava, T., Santo, A., Caldara, A., Cetto, G. L.

“…Background : Bisphosphonates (BPs) are the mainstay of bone-directed therapy for bone metastases from multiple myelomas and a wide range of solid tumours, but…”
Get full text

Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site by PIGA, A, NORTILLI, R, MONTIRONI, R, GESUITA, R, CARLE, F, CELLERINO, R, CETTO, G. L, CARDARELLI, N, FEDELI, S. Luzi, FIORENTINI, G, D'APRILE, M, GIORGI, F, PARZIALE, A. P, CONTU, A

“…The aim of this study was to assess the activity and toxicity of a platinum-based treatment on a group of patients with unknown primary tumours (UPTs)…”
Get full text

bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer by BONETTI, A, ZANINELLI, M, LEONE, R, CETTO, G. L, PELOSI, G, BIOLO, S, MENGHI, A, MANFRIN, E, BONETTI, F, PIUBELLO, Q

“…Programmed cell death is an important determinant of the response to chemotherapy. Among the factors controlling this process, a significant role is played by…”
Get full text

Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer by CAPPUZZO, F, MAZZONI, F, TUMOLO, S, LUCENTINI, A, VALDUGA, F, BARTOLINI, S, CRINO, L, CONTE, P. F, GENNARI, A, DONATI, S, SALVADORI, B, ORLANDINI, C, CETTO, G. L, MOLINO, A, GALLIGIONI, E, MANSUTTI, M

“…In this phase II, multicentre trial, patients with metastatic breast cancer (MBC) were treated with a combination of gemcitabine, epirubicin and paclitaxel…”
Get full text

Neo-adjuvant chemotherapy in non-small cell lung cancer (NSCLC) by Santo, A., Genestreti, G., Sava, T., Manno, P., Terzi, A., Molino, A.M., Cetto, G.L.

Get full text

Gemcitabine and Continuous Infusion of 5-Fluorouracil in Locally Advanced and Metastatic Pancreatic Cancer: A Phase I-II Study by OLIANI, C, PADOVANI, M, MANNO, P, BARANA, I, FALCONI, M, BASSI, C, CAVALLINI, G, PEDERZOLI, P, CETTO, G. L

“…Background: Gemcitabine has been recently recognized as standard treatment in advanced pancreatic cancer. To potentiate its single-agent activity we conducted…”
Get full text

Comparative study of clinical, pathological and biological characteristics of symptomatic versus asymptomatic breast cancers by Molino, A., Pavarana, M., Micciolo, R., Nortilli, R., Pedersini, R., Manno, P., Bozzi, P., Bonetti, F., Piubello, Q., Cetto, L. G.

“…Background: It is well known that mammographic screening reduces breast cancer mortality. One possible explanation for this effect is that screening makes it…”
Get full text

Ki‐67 immunostaining in 322 primary breast cancers: Associations with clinical and pathological variables and prognosis by Molino, Annamaria, Micciolo, Rocco, Turazza, Monica, Bonetti, Franco, Piubello, Quirino, Bonetti, Andrea, Nortilli, Rolando, Pelosi, Giuseppe, Cetto, Gian Luigi

“…Cell‐proliferation markers are very important in the clinical management of cancer patients, and the identification of Ki‐67 (a monoclonal antibody that…”
Get full text

Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients by Chiarion Sileni, V, Nortilli, R, Aversa, S M, Paccagnella, A, Medici, M, Corti, L, Favaretto, A G, Cetto, G L, Monfardini, S

“…This randomized phase II trial was performed to define the activity and toxicity of the combination of dacarbazine (DTIC), carmustine (BCNU), cisplatin (DDP)…”
Get full text

Use of the ratio of time to progression following first-and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma by Bonetti, A., Zaninelli, M., Leone, R., Franceschi, T., Fraccon, A. P., Pasini, F., Sabbioni, R., Cetto, G. L., Sich, D., Brienza, S., Howell, S. B.

“…Background: It has been proposed that the activity of a second-line treatment regimen can be documented by showing that the time to progression (TTP) following…”
Get full text

Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy by BONETTI, A, APOSTOLI, P, ZANINELLI, M, PAVANEL, F, COLOMBATTI, M, CETTO, G. L, FRANCESCHI, T, SPEROTTO, L, LEONE, R

“…Platinum-DNA adducts can be assayed in peripheral blood leukocytes by means of atomic absorption spectroscopy and ELISA, and high adduct levels have been…”
Get full text

Prognostic significance of estrogen receptors in 405 primary breast cancers : a comparison of immunohistochemical and biochemical methods by MOLINO, A, MICCIOLO, R, BONETTI, A, NORTILLI, R, TOMEZZOLI, A, POLLINI, G. P, MODENA, S, CETTO, G. L, TURAZZA, M, BONETTI, F, PIUBELLO, Q, CORGNATI, A, SPEROTTO, L, RECALDIN, E, SPAGNOLLI, P, MANFRIN, E

“…Over the last few years, estrogen receptor determination by means of immunohistochemistry has been extensively used. The aim of this study was to compare this…”
Get full text

A phase II study of induction chemotherapy with gemcitabine (G) and cisplatin (P) in locally advanced non-small cell lung cancer: interim analysis by Santo, Antonio, Pedersini, R, Pasini, F, Terzi, A, Pari, F, Cartei, G, Sibau, A, Molino, A, Maiorino, A, Panza, N, Oletti, M.V, Maluta, S, Calabrò, F, Cetto, G.L

“…Background: Gemcitabine–cisplatin (GP) combination is one of the most active and well tolerated regimens in advanced non-small cell lung cancer (NSCLC). The…”
Get full text